We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Biomarker Test to Enable Accurate Diagnosis of Diabetic Kidney Disease

By LabMedica International staff writers
Posted on 20 Jul 2023

Diabetic kidney disease (DKD), a major microvascular complication of type 2 diabetes mellitus (T2DM), results in permanent kidney damage and poor prognosis for the affected patients. More...

For individuals with T2DM, particularly those with a prolonged disease history, early detection and monitoring of kidney damage are critical. Now, a team of researchers who conducted a comprehensive analysis of urinary and exosome proteome profiling has uncovered novel biomarkers for DKD.

In a collaborative study involving researchers from the Chinese Academy of Sciences (Shanghai, China), the team carried out extensive urinary proteomics and urinary exosome proteomics studies on T2DM patients exhibiting varying levels of albuminuria. The study involved 144 clinical patients, from whom 144 urine samples were collected. This included 19 healthy controls and 125 T2DM patients at various stages (74 at DM1 stage with ACR value < 30 mg/g, 36 at DM2 stage with 30 mg/g ≤ ACR value ≤ 300 mg/g, and 15 at DM3 stage with ACR value > 300 mg/g). This helped the team uncover the dynamic attributes of urinary and exosome proteomes in T2DM patients with varying albuminuria levels. All proteins were grouped into six clusters based on their expression patterns throughout DKD's progression.

The research revealed that proteins involved in glycolysis and ubiquitination processes experienced a dramatic drop from healthy control to DM1 stage, followed by a slow decline from DM1 to DM3 stage. Proteins associated with lipid transport and cholesterol esterification progressively increased as DKD advanced, peaking at the DM3 stage. Proteins mainly engaged in carbohydrate metabolic processes exhibited high expression in T2DM patients and then decreased as DKD progressed. Moreover, the team identified and validated a series of proteins like SERPINA1 and TF in another cohort of diabetic urine samples at different DKD stages. These proteins hold potential as future biomarkers for DKD diagnosis or disease monitoring, thereby offering a valuable resource for identifying potential urinary biomarkers in DKD patients.

Related Links:
Chinese Academy of Sciences 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.